School of Public Health, Weifang Medical University, Weifang, PR China.
Qingdao Stomatological Hospital, Qingdao, PR China.
Public Health. 2023 Nov;224:140-151. doi: 10.1016/j.puhe.2023.08.034. Epub 2023 Oct 3.
The aim of this study was to systematically evaluate the current economic burden of coronary heart disease (CHD) in mainland China and provide a reference for the formulation of policies to reduce the economic burden of CHD.
A systematic literature review was conducted of empirical studies on the economic burden of CHD over the past 20 years.
PubMed, Web of Science, Embase, China Knowledge Resource Integrated Database and the WANFANG database were comprehensively searched for relevant articles published between 1 January 2000 and 22 December 2021. Content analysis was used to extract the data, and Stata 17.0 software was used for analysis. The median values were used to describe trends.
A total of 35 studies were included in this review. The annual median per-capita hospitalisation expense and the average expense per hospitalisation were $3544.40 ($891.64-$18,371.46) and $5407.34 ($1139.93-$8277.55), respectively. The median ratio on medical consumables expenses, drug expenses, medical examination expenses and treatment expenses were 41.59% (12.40%-63.73%), 26.90% (7.30%-60.00%), 9.45% (1.65%-33.40%) and 10.10% (2.36%-66.00%), respectively. The median per-capita hospitalisation expense in the eastern, central and western regions were $9374.45 ($2056.13-$18,371.46), $4751.5 ($2951.95-$8768.93) and $3251.25 ($891.64-$13,986.38), respectively. The median average expense per hospitalisation in the eastern and central regions were $6177.15 ($1679.15-$8277.55) and $1285.49 ($1239.93-$2197.36), respectively. The median average length of stay in the eastern, central and western regions were 9.3 days, 15.2 days and 16.1 days, respectively.
The economic burden of CHD is more severe in mainland China than in developed countries, especially in terms of the direct economic burden. In terms of the types of direct medical expenses, a proportion of medical examination expenses, treatment expenses and drug expenses were lowest in the eastern region, but medical consumables expenses were the highest in this region. This study provides guidance for the formulation of policies to reduce the economic burden of CHD in mainland China.
本研究旨在系统评估中国大陆地区冠心病的经济负担现状，为减轻冠心病经济负担的政策制定提供参考。
对过去 20 年冠心病经济负担的实证研究进行系统文献回顾。
全面检索 2000 年 1 月 1 日至 2021 年 12 月 22 日PubMed、Web of Science、Embase、中国知识资源总库和万方数据库中相关文章。采用内容分析法提取数据，使用 Stata 17.0 软件进行分析。采用中位数描述趋势。
共纳入 35 项研究。冠心病患者年人均住院费用和人均住院次均费用中位数分别为 3544.40 美元（891.64-18371.46 美元）和 5407.34 美元（1139.93-8277.55 美元）。医疗耗材、药品、检查和治疗费用的中位数占比分别为 41.59%（12.40%-63.73%）、26.90%（7.30%-60.00%）、9.45%（1.65%-33.40%）和 10.10%（2.36%-66.00%）。东部、中部和西部地区冠心病患者年人均住院费用中位数分别为 9374.45 美元（2056.13-18371.46 美元）、4751.5 美元（2951.95-8768.93 美元）和 3251.25 美元（891.64-13986.38 美元）。东部和中部地区冠心病患者人均住院次均费用中位数分别为 6177.15 美元（1679.15-8277.55 美元）和 1285.49 美元（1239.93-2197.36 美元）。东部、中部和西部地区冠心病患者平均住院日中位数分别为 9.3 天、15.2 天和 16.1 天。
与发达国家相比，中国内地地区冠心病的经济负担更为严重，特别是直接经济负担。在直接医疗费用类型方面，东部地区检查费用、治疗费用和药品费用比例最低，而耗材费用最高。本研究为中国内地减轻冠心病经济负担政策的制定提供了依据。
